| P2093 | author name string | Thomas Hermanns | |
| | Daniel Eberli | |
| | Lars Husmann | |
| | Julian Müller | |
| | Irene A Burger | |
| | Michael Messerli | |
| | Jan H Rüschoff | |
| | Daniela A Ferraro | |
| | Urs J Muehlematter | |
| | Niels J Rupp | |
| | Benedikt Kranzbühler | |
| P2860 | cites work | Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer | Q28236013 |
| | Prostate-specific membrane antigen expression as a predictor of prostate cancer progression | Q28289877 |
| | Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients | Q33841484 |
| | Immunohistochemical validation of PSMA-expression measured by (68)Ga-PSMA PET/CT in primary prostate cancer. | Q38642316 |
| | (68)Ga-HBED-CC-PSMA PET/CT Versus Histopathology in Primary Localized Prostate Cancer: A Voxel-Wise Comparison. | Q39572115 |
| | (68)Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study. | Q40243006 |
| | Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer | Q41038146 |
| | Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases | Q42456087 |
| | Robotic-assisted laparoscopic extended pelvic lymph node dissection for prostate cancer: surgical technique and experience with the first 99 cases | Q42607108 |
| | Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues | Q44962356 |
| | High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer | Q44994966 |
| | 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. | Q46225464 |
| | PROstate cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. | Q46823336 |
| | Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease | Q47781853 |
| | Treatment Outcomes from 68Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET. | Q48023733 |
| | A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer | Q48030260 |
| | Clinical impact of PSMA-based 18F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy. | Q48089415 |
| | 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour | Q48295687 |
| | The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours | Q48844213 |
| | Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. | Q50103884 |
| | Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells. | Q52597201 |
| | PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis. | Q55020746 |
| | Impact of Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis | Q57108628 |
| | Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis | Q60943477 |
| | Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases | Q77378855 |
| | Prostate-specific membrane antigen expression in normal and malignant human tissues | Q77553386 |
| | Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis | Q81999680 |
| | Prostate-Specific Membrane Antigen-Negative Metastases-A Potential Pitfall in Prostate-Specific Membrane Antigen PET | Q88369849 |
| | [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study | Q88645082 |
| | Reproducibility of standardized uptake values of same-day randomized 68Ga-PSMA-11 PET/CT and PET/MR scans in recurrent prostate cancer patients | Q89459677 |
| | First Clinicopathologic Evidence of a Non-PSMA-Related Uptake Mechanism for 68Ga-PSMA-11 in Salivary Glands | Q91429074 |
| | Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer | Q92182846 |
| | Risk of metastatic disease on 68 gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer | Q92372702 |
| | Prospective, Multisite, International Comparison of 18F-Fluoromethylcholine PET/CT, Multiparametric MRI, and 68Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Pat | Q93159970 |
| | Clinical impact of 68Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction | Q93384512 |
| P433 | issue | 14 | |
| P921 | main subject | immunohistochemistry | Q899285 |
| P304 | page(s) | 6082-6094 | |
| P577 | publication date | 2020-05-15 | |
| P1433 | published in | Theranostics | Q21051383 |
| P1476 | title | Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with 68Ga-PSMA-11-PET | |
| P478 | volume | 10 | |